Key Details
Price
$20.00Annual Revenue
$27.70 KAnnual ROE
352.58%Beta
-0.26Events Calendar
Next earnings date:
May 13, 2025Recent quarterly earnings:
Nov 14, 2024Recent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Oct 27, 2023Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
TROY, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces plans for a second collaborative study with the University of Delaware. This new study aims to further explore the potential applications of ZIVO's proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus a.
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J. Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to di.
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today provided an update on activities related to licensing its product targeting coccidiosis in broiler chickens. Following the announcement in August 2024 of positive results from a 42-day coccidiosis study, the Company has been engaged in discussions.
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, reports favorable results from a study conducted in collaboration with the University of Delaware that evaluated the potential of ZIVO's proprietary active ingredients to reduce the transmission of Low Pathogenicity Avian Influenza (LPAI) virus among po.
FAQ
- What is the ticker symbol for ZIVO Bioscience?
- Does ZIVO Bioscience pay dividends?
- What sector is ZIVO Bioscience in?
- What industry is ZIVO Bioscience in?
- What country is ZIVO Bioscience based in?
- When did ZIVO Bioscience go public?
- Is ZIVO Bioscience in the S&P 500?
- Is ZIVO Bioscience in the NASDAQ 100?
- Is ZIVO Bioscience in the Dow Jones?
- When was ZIVO Bioscience's last earnings report?
- When does ZIVO Bioscience report earnings?
- Should I buy ZIVO Bioscience stock now?